Montreal, April 17, 2023 – CanVECTOR's Clinical Trials & Shared Platforms platform recently concluded the 2022 Pilot Study Funding Competition. Following an independent evaluation by scientific and patient partner reviewers, we are pleased to announce that we've awarded $100,000 to principal investigator Federico Germini, MD - McMaster University and the team for the study titled Rivaroxaban Versus Low Molecular Weight Heparin (LMWH) for Extended Venous Thromboembolism (VTE) Prophylaxis After Hip Fracture Surgery: a Pilot Randomized Trial.
Read More